AKT1 and colorectal carcinoma: Given that anti-EMT (epithelial–mesenchymal transition) effects of KY1022, a β-catenin destabilizer, were reported in our previous study [20,21], we aimed to test whether KY1022 suppresses the AKT-inhibitor-mediated cell migration in CRC cells.